# Autolus Therapeutics share price today (Autolus Therapeutics plc, AUTL)

> Autolus Therapeutics plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AUTL · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/autl

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.38 (+3.8% in a year)
- Revenue (Jun 2026): $45.7 M (+118.4% on a year ago)
- Profit (Jun 2026): −$39.1 M
- Operating margin: −95.9% (+196.7 points on a year ago)
- ROE: −161%, FY25
- ROIC: −28.1%, against a 12.9% cost of capital: −41.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Autolus Therapeutics share price today? Autolus Therapeutics plc's share price was $1.38 at the close on 4 November 2026. That is 17.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $2, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved −44% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Autolus Therapeutics pay? Autolus Therapeutics plc pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Autolus Therapeutics on? Autolus Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Autolus Therapeutics profitable? Autolus Therapeutics plc posted a net loss of $39.1 M in the Jun 2026 quarter. The full FY25 year was a loss of $288 M. That loss is 85.6% of the quarter's revenue. The same quarter a year earlier lost $47.9 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Autolus Therapeutics make, and is it growing? Autolus Therapeutics plc reported $45.7 M of revenue in the Jun 2026 quarter, +118.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 138.5% a year on average. The last full year, FY25, came in at $75.4 M. The last four reported quarters add to $117 M. FY25 revenue was $75.4 M, +644.9% on the year before. Recent pace: the last four quarters grew +155.2% on average, against 138.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +193.3%, against +303.2% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Autolus Therapeutics keep? Autolus Therapeutics plc's operating margin was −95.9% in the Jun 2026 quarter, 196.7 percentage points higher than the same quarter a year ago. Across 5 years it has been between −10,337.3% and −358.4%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +196.7 percentage points on the year while gross margin changed +142.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Autolus Therapeutics' profit turning into cash? Autolus Therapeutics plc's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $284 M of cash, against −$288 M of profit. After $19.0 M of spending on assets, free cash was −$303 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Autolus Therapeutics' cash go? Autolus Therapeutics plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $52.1 M on assets over the last 3 years. Averaged over those years that is 23.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $52.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Autolus Therapeutics' P/E ratio, and how does it compare with its own history? Autolus Therapeutics plc has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Autolus Therapeutics plc at 4.9× its FY25 revenue of $75.4 M. The P/E comes back here once profit turns positive. ## Is the Autolus Therapeutics business getting better or worse? Autolus Therapeutics plc's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Autolus Therapeutics earn on its capital? Autolus Therapeutics plc earned a ROE of −161% in FY25. That is up from a low of −187% in FY23. Its return on capital used (ROIC) is 41.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −381.4% net margin and 0.13× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −381.4% net margin × 0.13× asset turnover × 3.31× leverage (assets divided by equity) ≈ −164.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −28.1% − 12.9% = −41.0 percentage points. The 12.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Autolus Therapeutics have too much debt? Autolus Therapeutics plc has total debt of $368 M against shareholder equity of $74.8 M as of Jun 2026, so its debt is 4.91× its equity. Year by year, that ratio went from 0.22 in FY21 to 1.92 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Autolus Therapeutics shareholding pattern? We have no ownership or short-position figures for Autolus Therapeutics plc, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 5.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Autolus Therapeutics from balance-sheet trouble? For Autolus Therapeutics plc, the Z-score is −4.39. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −4.39 is inside the danger zone, so the balance sheet is a real risk. ## How does Autolus Therapeutics rank in its industry? There is no score against its industry: Autolus Therapeutics plc is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Autolus Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Autolus Therapeutics in size? Autolus Therapeutics is the 160th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: C4 Therapeutics, Inc., Avalo Therapeutics, Inc. and Lyell Immunopharma, Inc. Just below it: Fennec Pharmaceuticals Inc., Orchestra BioMed Holdings, Inc. and Opus Genetics, Inc. ### Biotechnology companies close in size

1. [C4 Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cccc) $384 million
2. [Avalo Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/avtx) $379 million
3. [Lyell Immunopharma, Inc.](https://www.sectoralpha.in/us/stocks/lyel) $378 million
4. Autolus Therapeutics plc $367 million
5. [Fennec Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/fenc) $363 million
6. [Orchestra BioMed Holdings, Inc.](https://www.sectoralpha.in/us/stocks/obio) $361 million
7. [Opus Genetics, Inc.](https://www.sectoralpha.in/us/stocks/ird) $355 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Virgin Galactic Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spce) $379 million · Aerospace & Defense
2. [Fossil Group, Inc.](https://www.sectoralpha.in/us/stocks/fosl) $379 million · Footwear & Accessories
3. Autolus Therapeutics plc $377 million
4. [mF International Limited](https://www.sectoralpha.in/us/stocks/mfi) $376 million · Software - Application
5. [Fennec Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/fenc) $375 million · Biotechnology

## What else do people ask about Autolus Therapeutics? ### What were Autolus Therapeutics's latest quarterly results? Autolus Therapeutics plc reported revenue of $45.7 M and a net loss of $39.1 M for the Jun 2026 quarter. Earnings per share were −$0.15. The operating margin was −95.9%, 196.7 percentage points higher than a year earlier (as of 4 November 2026). ### What is Autolus Therapeutics's market cap? Autolus Therapeutics plc's market capitalisation is $367 M at a stock price of $1.38. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Autolus Therapeutics performing? Autolus Therapeutics plc's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Autolus Therapeutics's stock price go up? This page does not forecast Autolus Therapeutics plc's stock price. What it shows instead: the stock price is $1.38. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Autolus Therapeutics in its business cycle? Autolus Therapeutics plc's FY25 operating margin was −358.4%, against a 5-year range of −10,337.3% to −358.4%: the middle of its own range, neither a peak nor a low. The latest quarter was −95.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Autolus Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Autolus Therapeutics a stock worth studying right now? What the numbers show: Autolus Therapeutics plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.